Patients with N3 non-small cell lung cancer (NSCLC) treated with radical chemoradiation can expect similar survival to patients with N2 disease. (January 2019) - Gomberg, S.; Hiley, C.; Taylor, B.; Smith, D.; Ahmad, S.